The tweet was deleted by the author.
But we saved everything 🙂.
Arcus Biosciences posted an update on its second-quarter financial results and clinical-stage pipeline through its official account. At the same time, Arcus Biosciences stock is down 3.8% on the day at $27.7.
The company used its own account to share details about its recent financial performance and developments in its clinical-stage pipeline. The post referenced the ARC-20 platform study and highlighted strategic clinical collaborations. The announcement did not specify new programs or changes to the business and serves mainly as an update on ongoing work.
View post on X Loading...
The post itself did not trigger any direct market response, as its timing and content do not link to the session’s price action. Instead, traders focused on evolving technical signals, with Arcus Biosciences stock slipping below the MA-20 at $28.38 during the session after previously closing above it. This shift left the price between key levels, below the MA-20 but supported by the MA-50 and MA-200, creating a split daily structure that is not fully resolved by current news. The broader bullish chart remains in play, but the immediate technical picture suggests hesitation around near-term resistance.
Traders should watch whether the stock can reclaim and hold above the MA-20 at $28.38 to gauge renewed buying interest. The loss of that level during the session stands out as the most decisive move so far. Even so, from here there is a very high probability—over 80%—of upside over the next five trading days, versus a very low probability—less than 20%—of a downside move, with an expected trading range of $26.82 to $28.57. A close back above $28.38 would confirm buyers are willing to follow through, while a drop below $27 would suggest the recent move is being faded. On the weekly chart, the longer-term picture for Arcus Biosciences stock stays firmly constructive.
Earlier, analysts noted that Arcus Biosciences maintained a constructive bullish trend despite some short-term volatility and technical pullbacks. The current update reinforces the focus on technical inflection points, with the next decisive move likely hinging on whether the stock can reclaim and hold above the MA-20 at $28.38.